Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Sparta to develop new camptothecin formulations

April 5, 1996

New daunorubicin derivative from P&U

April 5, 1996

Spartaject busulfan to enter phase I

April 5, 1996

FDA approves expanded labeling for Ethyol

March 15, 1996

Multidrug resistance modulator from Pfizer

March 15, 1996

Xenova to evaluate MDR modulator in phase I

March 15, 1996

MethylGene established to study antisense drugs for cancer indications

March 15, 1996

Eisai describes antitumor sulfonamide

March 15, 1996

OM-174 shows in vivo antitumor activity

March 15, 1996

Glaxo Wellcome reports antitumor drugs

March 15, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...